ADAG Adagene Inc. Annual reports only
Pharmaceutical Preparations · Nasdaq · SEC CIK 1818838 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY7,332.8%
TTM net income YoY47.3%
TTM EPS YoY49.2%
Revenue 3-yr CAGR-6.2%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-279.5%
Net margin-229.6%
FCF margin-204.3%
EBITDA margin-273.8%
Returns
ROE-41.0%
ROA-21.0%
ROIC (approx.)—
Asset turnover0.09x
Leverage & solvency
Liabilities / assets33.7%
Debt / equity0.17x
Current ratio3.07x
Interest coverage-46.29x
Cash quality & payout
Operating cash flow / net income0.89x
Accruals ratio-2.3%
Payout ratio—
Capex / revenue0.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $7.67M | $103,204 |
| R&D expense | $22.03M | $28.78M |
| SG&A expense | $7.08M | $7.27M |
| Operating income | -$21.44M | -$35.95M |
| Interest expense | $463,132 | $851,874 |
| Pretax income | -$17.91M | -$33.44M |
| Income tax | -$297,860 | -$17,553 |
| Net income | -$17.61M | -$33.42M |
| EBITDA | -$21.00M | -$35.23M |
| EPS (basic) | -0.30 | -0.59 |
| EPS (diluted) | -0.30 | -0.59 |
| Weighted avg. shares (diluted) | 59.01M | 56.29M |
| Balance sheet | ||
| Cash & equivalents | $74.52M | $85.19M |
| Short-term investments | $0 | $0 |
| Current assets | $77.38M | $87.78M |
| PP&E, net | $717,374 | $1.13M |
| Total assets | $78.26M | $89.27M |
| Current liabilities | $25.17M | $38.18M |
| Short-term debt | $4.98M | $17.79M |
| Long-term debt | $1.14M | $417,339 |
| Total debt | $6.12M | $18.21M |
| Total liabilities | $26.36M | $38.74M |
| Shareholders' equity | $35.35M | $50.52M |
| Net debt | -$68.41M | -$66.98M |
| Shares outstanding | 59.23M | 58.89M |
| Cash flow statement | ||
| Operating cash flow | -$15.66M | -$29.70M |
| Capital expenditure | $17,053 | $33,580 |
| Free cash flow | -$15.67M | -$29.73M |
| Investing cash flow | $476,803 | $1.11M |
| Financing cash flow | $4.45M | $3.77M |
| Depreciation & amortization | $438,864 | $722,950 |
| Stock-based compensation | $3.74M | $4.91M |
Free plan shows the latest 2 periods; Pro shows all 8 🔒
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.